REGENERON PHARMACEUTICALS, INC. Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount
REGENERON PHARMACEUTICALS, INC. (REGN) reported Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount of $29.00 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-02-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount · last filed 2025-02-05
- REGENERON PHARMACEUTICALS, INC. equity securities without readily determinable fair value, impairment loss, annual amount for the quarter ending 2023-09-30 was $29.00M.
- REGENERON PHARMACEUTICALS, INC. equity securities without readily determinable fair value, impairment loss, annual amount for fiscal 2023 was $29.00M.
| Period end | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 3 month | Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount 12 month |
|---|---|---|
| 2023-12-31 | $29.00M 10-K · filed 2025-02-05 | |
| 2023-09-30 | $29.00M 10-Q · filed 2024-10-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 |